Aluminum Sulfate, Hydrated (ACS & FCC): ORAL (LD50):
Acute: >9000 mg/kg in the mouse MSDS. >9000 mg/kg in the rat MSDS.
Acute Toxicity
There is little indication that aluminum is acutely toxic by oral exposure despite it is widely found in foods, drinking water, and many antacid preparations L2149. In 1988, a population of about 20 000 citizens of Camelford, England, was exposed to increased levels of aluminum for 5 days. The aluminum was accidentally ingested by the population from a water supply facility using aluminum sulfate for water treatment L2149.
Some adverse effects observed were nausea, vomiting, diarrhea, mouth ulcers, skin ulcers, skin rashes, and arthritis-type pain were observed. It was concluded in one study that the adverse effects of aluminum sulfate were primarily mild and transient. No long-lasting effects on health could be attributed to the exposures from aluminum in the drinking water during this period L2149.
Chronic Toxicity
In humans, excess exposure to aluminum via dialysis water (aluminum sulfate) is a known etiological factor in several pathological conditions in patients treated with hemodialysis. Clinical symptoms and signs of aluminum toxicity include hypercalcemia, anemia, vitamin D refractory osteodystrophy, and a dialysis encephalopathy. Bone pain, pathological fractures, and proximal myopathy may occur. Aluminum has also been suggested as an etiology of several neurodegenerative diseases such as Alzheimer senile and pre-senile dementia, as well amyotrophic sclerosis. Despite this, the most recent investigations have failed to confirm this hypothesis. A study in man has verified a number of possible deleterious interactions of aluminum salts with phosphorous metabolism, especially in long-term ingestion of aluminum-containing antacids L2152.
It has been suggested that aluminum exposure is a risk factor for the development or acceleration of onset of Alzheimer disease (AD) in humans. The world health organization has completed a meta-analysis of 20 epidemiological studies done to test the hypothesis that aluminum in drinking-water is a risk factor for Alzheimer disease. Six studies on populations in Norway were considered of sufficiently high quality to meet the general criteria for exposure and outcome assessment and the adjustment for at least some confounding variables L2149.
Of six studies that examined the relationship between aluminum in drinking- water and dementia, three found a positive relationship, but three did not. However, each of the studies had significant deficiencies in the study design (e.g. ecological exposure assessment; failure to consider aluminum exposure from all sources and to control for important confounders, such as education, socioeconomic status, and family history; the use of surrogate outcome measures for AD; and selection bias) L2149.
In general, the relative risks determined were less than 2, with large confidence intervals, when the total aluminum concentration in drinking-water was 0.1 mg/L or higher. Due to the pathogenesis of AD and knowledge obtained from studies, it was concluded that the present epidemiological evidence does not support a causal association between AD and aluminum in drinking-water L2149.
In addition to the epidemiological studies that examined the relationship between AD and aluminum in drinking-water, two studies studied cognitive dysfunction in elderly populations in relation to the levels of aluminum in drinking water. The results proved conflicting. A study of 800 male subjects, age 80-89, drinking water containing aluminum concentrations up to 98 ?g/L found no relationship. The second study used “any evidence of mental impairment” as an outcome measure and found a relative risk of 1.72 at aluminum drinking-water concentrations above 85 ?g/L in 250 males. Such data are insufficient to show that aluminum is a cause of cognitive impairment in the elderly L2149.
Note on possible risk of breast cancer
Widespread concern has been raised regarding the exposure to aluminum in deodorant/antiperspirant products, with inconclusive results L2165, L2167, L2168, L2169. Results from a more recent case-control study suggest an association between underarm cosmetic use and aluminum concentration in breast tissue and breast cancer. The observed association of underarm cosmetic use with breast cancer was, however, limited to women who report using the products multiple times a day before age of 30 A32464.
Aluminum (Al), also spelled aluminum, chemical element, a lightweight, silvery-white metal of main Group 13 (IIIa, or boron group) of the periodic table L2148.
It is a chemical agent used in water purification, the pH regulation of garden soil, and other commercial or industrial applications. Medically, it is primarily used as a coagulating agent in minor cuts and abrasions as well as deodorant L2144.
Aluminum (Al) is ubiquitous and represents the third most common element in the Earth’s crust. It most commonly exists in a combined state with various other elements. Al is found in materials used in the pharmaceutical industry, and in manufactured foodstuffs, cosmetics, and tap water. By overcoming the body barriers, Al may infiltrate into the blood and lead to toxic effects in liver, bone and the central nervous system L2145.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Eltrombopag | Aluminum sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Aluminum sulfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferasirox | Aluminum sulfate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Aluminum sulfate. |
| Halofantrine | Aluminum sulfate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ursodeoxycholic acid | Aluminum sulfate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Aluminum sulfate can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Aluminum sulfate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Aluminum sulfate can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Aluminum sulfate can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Aluminum sulfate can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Obeticholic acid | Aluminum sulfate can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Aluminum sulfate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Aluminum sulfate can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Aluminum sulfate can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Aluminum sulfate can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| cis-Diamminechlorocholylglycinateplatinum(II) | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum sulfate. |
| Dehydrocholic acid | Aluminum sulfate can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Aluminum sulfate can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aramchol | The serum concentration of Aramchol can be decreased when it is combined with Aluminum sulfate. |
| Ox bile extract | The serum concentration of Ox bile extract can be decreased when it is combined with Aluminum sulfate. |
| Technetium Tc-99m oxidronate | The serum concentration of Technetium Tc-99m oxidronate can be increased when it is combined with Aluminum sulfate. |
| Phenytoin | Aluminum sulfate can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mephenytoin | Aluminum sulfate can cause a decrease in the absorption of Mephenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Carbamazepine | Aluminum sulfate can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenobarbital | Aluminum sulfate can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Phenobarbital | Aluminum sulfate can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxadustat | Aluminum sulfate can cause a decrease in the absorption of Roxadustat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vadadustat | The serum concentration of Vadadustat can be decreased when it is combined with Aluminum sulfate. |